logo
Plus   Neg
Share
Email

Merck Announces Post-hoc Analysis From KEYNOTE-189 Trial - Quick Facts

Merck (MRK) announced the first-time presentation of results from a post-hoc analysis of patients with liver or brain metastases from the Phase 3 KEYNOTE-189 trial. In the primary analysis of KEYNOTE-189, which included patients regardless of PD-L1 expression status, KEYTRUDA in combination with pemetrexed and platinum chemotherapy resulted in a statistically significant and clinically meaningful improvement in overall survival, reducing the risk of death by half compared to chemotherapy alone. The study also showed a significant improvement in progression-free survival compared to chemotherapy alone, the company said.

Merck reported that the findings showed KEYTRUDA in combination with chemotherapy reduced the risk of death by 38 percent in patients with liver metastases and by 59 percent in patients with brain metastases compared to chemotherapy alone. KEYTRUDA in combination with chemotherapy also improved progression-free survival, with a reduction in the risk of progression or death by 48 percent in patients with liver metastases and 58 percent in patients with brain metastases compared to chemotherapy alone.

KEYNOTE-189 was conducted in collaboration with Eli Lilly and Company, the makers of pemetrexed.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Morgan Stanley has cut its worst-case forecast on Tesla Inc.'s share price from the previous estimate of $97 to just $10, dealing another blow to the luxury electric car maker. The worst-case or "bear case" scenario by Morgan Stanley analysts takes into account the risk posed if Tesla misses its current sales outlook for China by about half. Snap Inc. on Monday announced the promotion of two executives as the company restructures its management team. The parent company of messaging app Snapchat said it has appointed Derek Andersen, currently its vice president of finance, as chief financial officer. The company also named interim CFO Lara Sweet as its first chief people officer. Both appointments are effective immediately. Nike Inc., Adidas AG and other footwear companies have urged U.S. President Donald Trump to reconsider his proposed tariffs on shoes imported from China, noting that any increase in the cost of importing shoes has a direct impact on the American footwear consumer. In a letter, more than 170 footwear companies have urged the President to immediately remove footwear from the proposed tariffs.
Follow RTT